People · Operator
Named in public records as an officer, director or promoter · active 2024–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vaxess Technologies, Inc. | — | Biotechnology | Series C | $138.2M | $269.9M | 2024 |
Matthew Dirckx at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Matthew Dirckx on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ann DeWitt | 1 | 10 |
| Peter Kolchinsky | 1 | 8 |
| Aaron Sandoski | 1 | 7 |
| Rachel Sha | 1 | 4 |
| Purnanand Sarma | 1 | 3 |
| Michael Schrader | 1 | 3 |
| Fenel Eloi | 1 | 3 |
| Mario Barro | 1 | 3 |
| James Connolly | 1 | 3 |
| Mark Tracy | 1 | 3 |
| Livio Valenti | 1 | 2 |
| Johannes Fruehauf | 1 | 2 |
| Shuenn Ho | 1 | 1 |
| Jonathan Kluge | 1 | 1 |
| Weiner Tilsner | 1 | 1 |
| Lynda Tussey | 1 | 1 |
| John Spiridigliozzi | 1 | 1 |
| Fenel M. Eloi | 1 | 1 |
| Livio M. Valenti | 1 | 1 |
| Jonathan M. Kluge | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.